Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK, Bioavailability, and Food Effect of Lu AF11167 in Healthy Subjects
NCT04104503Phase 1Completed
- Sponsor
- Lundbeck
- Start
- Sep 2019
- Primary completion
- Apr 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of Lu AF11167 in schizophrenia (4 arms), sponsored by Lundbeck. Primary endpoints: Maximum Plasma Concentration (Cmax) of Lu AF11167, Area Under the Curve (AUC0-inf) of Lu AF11167 and 2 more. Started Sep 2019; status: completed.
02
Drugs
Lu AF11167
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT04104503.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04104503.